Stryde® lengthening nail has been recently withdrawn because of concerns about osteolysis and other bone lesions that have been observed early after implantation. The present study analyses the incidence and features of these bone lesions in our patients.
Materials and Methods
This is a retrospective review of a series of patients from two centres specializing in limb reconstruction. Inclusion criteria was a history of surgery with Stryde® lengthening nail with more than one year follow-up available.
All postoperative x-rays were and clinical notes were reviewed.
36 patients with 75 bone segments were included.
11 (30.5%) patients and 32 (42.6%) bone segments were without any lesion.
In 3 (8.3%) patients and 3 (4%) segments, osteolytic lesions only were noticed.
11(30.5%) patients and 14 (18.6%) segments had combined lytic lesions and periosteal reaction or cortical thickening.
12 (33.3%) patients and 26 (34.6%) segments developed only periosteal reaction or cortical thickening.
54.8% of patients with bilateral nailing had bilateral lesions.
52% of the patients with bone lesions reported late onset of pain after the completion of the lengthening.
The average earliest interval that any of the lesions was noticed was 10.2 months post-surgery.
Patients with Stryde® nails should be monitored clinically and radiologically at regular intervals until removal.
The early failure and withdrawal of Precise Stryde® nail, is a significant event in the field of limb reconstruction; this study adds useful data to the growing pool of published data related to the this event.